Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 19,060 Shares

Posted by Amy Steele on Apr 25th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 19,060 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $14.13, for a total value of $269,317.80. Following the completion of the sale, the chief operating officer owned 390,808 shares of the company’s stock, valued at $5,522,117.04. The trade was a 4.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

On Friday, April 24th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.02, for a total value of $267,221.20.
On Tuesday, April 21st, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.66, for a total value of $453,595.06.
On Monday, April 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.55, for a total value of $277,323.00.
On Thursday, April 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.18, for a total value of $270,270.80.
On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.15, for a total value of $250,639.00.
On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.77, for a total value of $243,396.20.
On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.56, for a total value of $258,453.60.
On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total transaction of $458,855.03.
On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total transaction of $275,417.00.
On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.83, for a total transaction of $263,599.80.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $14.14 on Friday. The firm has a market cap of $2.18 billion, a PE ratio of -35.35 and a beta of 2.29. The firm’s 50 day moving average price is $14.50 and its two-hundred day moving average price is $15.97. Adaptive Biotechnologies Corporation has a twelve month low of $7.16 and a twelve month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. During the same quarter last year, the business posted ($0.23) EPS. The company’s revenue for the quarter was up 51.0% on a year-over-year basis. Equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.5 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Guggenheim upped their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. JPMorgan Chase & Co. raised their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday. Finally, Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research note on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $18.25.

View Our Latest Report on ADPT

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors and hedge funds have recently modified their holdings of ADPT. Allianz Asset Management GmbH increased its holdings in shares of Adaptive Biotechnologies by 305.8% during the 3rd quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after acquiring an additional 242,474 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Adaptive Biotechnologies by 82.5% in the 3rd quarter. SG Americas Securities LLC now owns 68,113 shares of the company’s stock valued at $1,019,000 after acquiring an additional 30,785 shares in the last quarter. Affinity Wealth Management LLC acquired a new stake in Adaptive Biotechnologies in the 3rd quarter worth approximately $4,541,000. Lisanti Capital Growth LLC acquired a new stake in Adaptive Biotechnologies in the 3rd quarter worth approximately $4,476,000. Finally, Aristotle Atlantic Partners LLC boosted its position in Adaptive Biotechnologies by 8.6% during the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company’s stock worth $46,776,000 after purchasing an additional 247,402 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.